Site is Being Upgraded

Taurine-based therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Taurine, an amino sulfonic acid,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 8/April/2018,  12.08 am

Natural product-derived therapy for cardiomyocyte proliferation and heart regeneration: A pharmaceutical mixture encompassing Sulforaphane, Myricitrin and Aspalathin (SMA) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 7/April/2018, 11.45 pm
April 7, 2018
An omega-3 way to treat pain:  PUFA-based activation of the PD-1 pathway for Pain therapy:  ω-PUFAs (Docosahexaenoic acid (DHA) + Eicosapentaenoic acid (EPA) increase the expression of PD-L1, attenuate acutes and chronic pain, suppress mechanical and thermal hypersensitivity and inhibit nociceptive neuron excitability, via up-regulation of its target gene, 9/April/2018, 6.31 am
April 9, 2018
Show all

Introduction: What they say

A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan 20157, Italy; and Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA shows that “PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.” This research paper was published, in the 15 November 2017 issue of the journal “Science Translational Medicine” [One of the best research journals in Science with an I.F of 15 plus], by Prof. Fiorina P and Nasr MB and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Taurine-based therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Taurine, an amino sulfonic acid,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (2) Type 1 Diabetes (T1DM) constitutes about 5-10% (11 to 12 million) of all diabetic cases; (3) the incidence of T1DM is exponentially increasing year after year by 3%; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, while treatment for T1DM costs about $15 billion dollars per annum, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM;(ii) a side-effect-free natural product-based drug that does not harm or deplete adult stem cells; and (iii) a way to cure, not just treat, diabetes.


What is known?

Prof. Fiorina’s research team has recently shown that:(1) programmed death ligand 1 (PD-L1), the immune checkpoint regulator, is expressed poorly in hematopoietic stem and progenitor cells (HSPCs) of Type-1 diabetic (T1D) patients; (2) PD-L1 inhibits activated T-cells and thereby promotes immune tolerance; (3) the expression of PD-L1 is controlled by a network of miRNAs; (4) attenuating the expression of one of the miRNAs that target PD-L1 restores the expression of PD-L1 in HSPCs; (5) increasing the expression of PD-L1 in HSPCs, either genetically or pharmacologically, inhibits autoimmune response and reverses autoimmune diabetes; and (6) PD-L1 is expressed poorly in human HSPCs of T1D patients, suggesting that increasing the expression of PD-L1 in T1D patients may reverse and cure T1D.


From research findings to Therapeutic opportunity:

This study suggests an amino sulfonic acid-based therapy for autoimmune diabetes. Taurine, by increasing the expression of its target gene, it may increase the expression of PD-L1. Thereby, they may: (1) increase Regulatory T-cells(Tregs) function; (2) decrease immune activation; (3) increase pancreatic-β-cell proliferation and regeneration; (4) increase expression of genes that promote insulin sensitivity and insulin secretion;(4) decrease metabolic stress; and (5) promote glucose homeostasis (Fig.1). Thus, physicians/diabetologists may consider adopting Taurine-based therapy in the treatment of autoimmune diabetes (T1DM).

Given the mechanism of action of taurineTaurine-based therapy may be used to  treat autoimmune diabetes (TiDM) (Fig.2).

Figure 1. Mechanistic insights into how taurine prevent the progression  of autoimmune diabetes (T1DM). Taurine, by increasing the expression of their target genes, they may increase the expression of PD-L1. Thereby, it may prevent immune activation and attenuate the development of T1DM.

Figure 2. Taurine-based therapy may aid in the treatment of autoimmune diabetes through induction of PD-L1


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How Taurine increases the expression of PD-L1?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Taurine-based therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Taurine, an amino sulfonic acid,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 8/April/2018,  12.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

Comments are closed.